LBA1 First-line ribociclib + letrozole in postmenopausal Asian women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): A subgroup analysis from MONALEESA-2-Reference-Cited by-同舟云学术

LBA1 First-line ribociclib + letrozole in postmenopausal Asian women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): A subgroup analysis from MONALEESA-2

Published:2016-12 Issue:suppl_9 Volume:27 Page:
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:

Author:

Yap Y.S.,Tseng L-M.,Blackwell K.L.,Cameron D.,Foo S.,Sriuranpong V.,Huang C-S.,Chao T-Y.,Kim T-Y.,Chen S-C.,Jung K.H.,Lee K.S.,Sohn J-H.,Kim J.H.,Hou M-F.,Han Y.,Souami F.,Dhuria S.,Miller M.,Verma S.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/suppl_9/mdw637.001/10242590/mdw637.001.pdf

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current treatment aspects of hormone-dependent ERBB2-negative metastatic breast cancer: overall survival outcomes;Journal of Modern Oncology;2022-07-15

2. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial;Nature Medicine;2021-11

3. An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer;Targeted Oncology;2021-09-28

4. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women;American Journal of Health-System Pharmacy;2019-08-01

5. The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis;Breast Cancer Research and Treatment;2018-11-21